Acetyl-L-carnitine vs Alpha-lipoic acid
The two supplements most often stacked together for diabetic nerve pain — both real, both hitting the same ceiling: symptoms improve, the nerve itself does not.
Short answer
Neither acetyl-L-carnitine nor alpha-lipoic acid needs a prescription, and both have human data, so the goal decides it. Acetyl-L-carnitine is marketed for cognitive function, mood, diabetic neuropathy and mitochondrial energy; alpha-lipoic acid is the choice for readers interested in nerve pain, blood sugar, weight loss and antioxidant support.
Acetyl-L-carnitine
ALCAR, levacecarnine
Real RCT data across three separate conditions, unusually deep for this bench — a large pooled effect for depression augmentation, a Cochrane 'very low certainty' verdict for diabetic neuropathy despite two positive trials, and an unsettled, decades-old literature for mild cognitive impairment.
Full Acetyl-L-carnitine evidence reviewAlpha-lipoic acid
Thioctic acid; NOT alpha-linolenic acid
Genuinely reduces diabetic neuropathy symptoms (licensed for it in Germany), but the 4-year NATHAN 1 trial missed its primary endpoint, weight loss is under a kilogram, and it can trigger autoimmune hypoglycemia in HLA-DRB1*04:06 carriers.
Full Alpha-lipoic acid evidence reviewAcetyl-L-carnitine vs Alpha-lipoic acid: head to head
- FDA status / approved use
Acetyl-L-carnitine
Sold as a dietary supplement; not FDA-approved for neuropathy, depression, or cognitive declineAlpha-lipoic acid
Approved drug for diabetic neuropathy in Germany; sold as an unapproved dietary supplement in the US- Marketed for
Acetyl-L-carnitine
Cognitive function, mood, diabetic neuropathy, mitochondrial energyAlpha-lipoic acid
Nerve pain, blood sugar, weight loss, antioxidant- Outcome areas
Acetyl-L-carnitine
Cognitive function / memory; Mood / anxiety / stress; Mitochondrial / cellular energyAlpha-lipoic acid
Blood sugar / insulin sensitivity; Weight loss / appetite- Evidence grade
Acetyl-L-carnitine
Clinical dataAlpha-lipoic acid
Clinical data- How it works
Acetyl-L-carnitine
Shuttles fatty acids into mitochondria via the carnitine shuttleAlpha-lipoic acid
Redox-active acid that acts on thiol and antioxidant systems and cell signaling- Route and dosing
Acetyl-L-carnitine
Oral, usually split two or three times dailyAlpha-lipoic acid
Oral capsule, typically 600 mg daily; given intravenously in Germany- Headline human result
Acetyl-L-carnitine
Depressive symptoms reduced vs placebo, SMD −1.10, in a 2018 meta-analysis of 12 RCTs (n=791)Alpha-lipoic acid
Oral 600 mg/day cut neuropathy symptom score 4.9 points (51%) vs 2.9 points (32%) on placebo in the SYDNEY 2 trial- Strongest evidence
Acetyl-L-carnitine
Veronese 2018 depression meta-analysis, Psychosom MedAcetyl-L-carnitine evidence reviewPubMed 29076953Alpha-lipoic acid
Ziegler 2004 meta-analysis, Diabet MedAlpha-lipoic acid evidence reviewPubMed 14984445- Key safety signal
Acetyl-L-carnitine
Generally well tolerated; mild nausea and other GI complaints are most commonAlpha-lipoic acid
Can trigger insulin autoimmune syndrome with severe low blood sugar, mainly in HLA-DRB1*04:06 carriers- How it is obtained
Acetyl-L-carnitine
Over the counter as a dietary supplementAlpha-lipoic acid
Over the counter as a dietary supplement
| Acetyl-L-carnitine | Alpha-lipoic acid | |
|---|---|---|
| FDA status / approved use | Sold as a dietary supplement; not FDA-approved for neuropathy, depression, or cognitive decline | Approved drug for diabetic neuropathy in Germany; sold as an unapproved dietary supplement in the US |
| Marketed for | Cognitive function, mood, diabetic neuropathy, mitochondrial energy | Nerve pain, blood sugar, weight loss, antioxidant |
| Outcome areas | Cognitive function / memory; Mood / anxiety / stress; Mitochondrial / cellular energy | Blood sugar / insulin sensitivity; Weight loss / appetite |
| Evidence grade | Clinical data | Clinical data |
| How it works | Shuttles fatty acids into mitochondria via the carnitine shuttle | Redox-active acid that acts on thiol and antioxidant systems and cell signaling |
| Route and dosing | Oral, usually split two or three times daily | Oral capsule, typically 600 mg daily; given intravenously in Germany |
| Headline human result | Depressive symptoms reduced vs placebo, SMD −1.10, in a 2018 meta-analysis of 12 RCTs (n=791) | Oral 600 mg/day cut neuropathy symptom score 4.9 points (51%) vs 2.9 points (32%) on placebo in the SYDNEY 2 trial |
| Strongest evidence | Veronese 2018 depression meta-analysis, Psychosom MedAcetyl-L-carnitine evidence reviewPubMed 29076953 | Ziegler 2004 meta-analysis, Diabet MedAlpha-lipoic acid evidence reviewPubMed 14984445 |
| Key safety signal | Generally well tolerated; mild nausea and other GI complaints are most common | Can trigger insulin autoimmune syndrome with severe low blood sugar, mainly in HLA-DRB1*04:06 carriers |
| How it is obtained | Over the counter as a dietary supplement | Over the counter as a dietary supplement |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Alpha-lipoic acid has the deeper trial program (pooled IV trials, oral RCTs, and the four-year NATHAN 1 study), with a ~24% relative symptom improvement over placebo but no effect on nerve conduction or NATHAN 1's primary endpoint. Acetyl-L-carnitine has two positive pooled RCTs in the same population, though a 2019 Cochrane review still rated the certainty 'very low.' Different mechanisms — antioxidant vs. mitochondrial fatty-acid shuttle — the same wall.
Acetyl-L-carnitine fits if
You also want the mood-related depression-augmentation evidence acetyl-L-carnitine has that alpha-lipoic acid doesn't.
Alpha-lipoic acid fits if
You want the larger, more consistent trial base specifically for diabetic neuropathy symptoms, and you're aware of the rare autoimmune hypoglycemia risk in certain HLA carriers.
Acetyl-L-carnitine vs Alpha-lipoic acid: common questions
- Is either acetyl-L-carnitine or alpha-lipoic acid FDA-approved?
- No. Acetyl-L-carnitine is sold as a dietary supplement; not FDA-approved for neuropathy, depression, or cognitive decline. Alpha-lipoic acid is an approved drug for diabetic neuropathy in Germany; sold as an unapproved dietary supplement in the US.
- Which has stronger human evidence, acetyl-L-carnitine or alpha-lipoic acid?
- Neither clearly. Both have human clinical data. The key source for acetyl-L-carnitine is Veronese 2018 depression meta-analysis, Psychosom Med; for alpha-lipoic acid, it is Ziegler 2004 meta-analysis, Diabet Med.
- What are the main safety concerns with acetyl-L-carnitine and alpha-lipoic acid?
- Acetyl-L-carnitine is generally well tolerated; mild nausea and other GI complaints are most common. Alpha-lipoic acid can trigger insulin autoimmune syndrome with severe low blood sugar, mainly in HLA-DRB1*04:06 carriers.
Key studies behind each
Acetyl-L-carnitine
- Knottnerus SJG, Bleeker JC, Wüst RCI, et al. (2018). Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. Rev Endocr Metab Disord. PubMed 29926323
- Xiang F, Zhang Z, Xie J, et al. (2025). Comprehensive review of the expanding roles of the carnitine pool in metabolic physiology: beyond fatty acid oxidation. J Transl Med. PubMed 40087749
- De Grandis D, Minardi C. (2002). Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D. PubMed 12455197
- Sima AA, Calvani M, Mehra M, Amato A; Acetyl-L-Carnitine Study Group. (2005). Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care. PubMed 15616239
Alpha-lipoic acid
- Cronan JE. (2016). Assembly of Lipoic Acid on Its Cognate Enzymes: an Extraordinary and Essential Biosynthetic Pathway. Microbiol Mol Biol Rev. PubMed 27074917
- Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. (2009). Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. PubMed 19664690
- Keith DJ, Butler JA, Bemer B, et al. (2012). Age and gender dependent bioavailability of R- and R,S-α-lipoic acid: a pilot study. Pharmacol Res. PubMed 22609537
- Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. (2004). Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. PubMed 14984445
The full evidence reviews
- Acetyl-L-Carnitine (ALCAR): Evidence for Neuropathy, Depression and Cognition
Real mitochondrial mechanism and RCT data in three conditions — strongest for depression augmentation, mixed for neuropathy, unsettled for cognitive impairment.
Updated August 2026
- Alpha-Lipoic Acid: Evidence, Dosing and Safety
Alpha-lipoic acid is a licensed neuropathy drug in Germany and an unapproved supplement in the US — with strong diabetic-neuropathy data, a marginal ~0.7 kg weight effect, and a real, ancestry-linked risk of autoimmune hypoglycemia.
Updated August 2026